慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease, COPD)作为临床呼吸系统常见疾病之一,具有高患病率和高死亡率的特点,严重影响着慢性阻塞性肺疾病患者的生活质量,并给社会、家庭带来较大的经济和心理负担。常规西医治疗本病...慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease, COPD)作为临床呼吸系统常见疾病之一,具有高患病率和高死亡率的特点,严重影响着慢性阻塞性肺疾病患者的生活质量,并给社会、家庭带来较大的经济和心理负担。常规西医治疗本病主要以积极对症治疗为主,而中医药对治疗慢性阻塞性肺疾病往往具有较好的临床疗效。本文通过分析近年来大量相关文献和临床研究,并结合中医药在临床辨治慢性阻塞性肺疾病的实际疗效,得出“从痰瘀论治慢性阻塞性肺疾病的临床效果较佳”,故以“痰瘀互结”理论为角度,从痰瘀型慢性阻塞性肺疾病的理论依据、临床治疗出发作出综述,为中医药临床从痰瘀治疗该病提供理论依据。Chronic Obstructive Pulmonary Disease (COPD), as one of the common diseases of clinical respiratory system, has the characteristics of the high morbidity and high mortality rate, which seriously affects the quality of life of patients with chronic obstructive pulmonary disease and brings a larger economic and psychological burden on society and family. Conventional Western medicine mainly focuses on the positive symptomatic treatment of this disease, while traditional Chinese medicine often has better clinical efficacy in the treatment of chronic obstructive pulmonary disease. Through analyzing a large number of relevant literature and clinical studies in recent years and combining with the actual therapeutic effect of traditional Chinese medicine in the clinical differentiation of chronic obstructive pulmonary disease, this paper concludes that “the clinical effect of treating chronic obstructive pulmonary disease from phlegm and blood stasis is better”. Therefore, based on the theory of “interjunction of phlegm and blood stasis”, this paper summarizes the theoretical basis and clinical treatment of chronic obstructive pulmonary disease with phlegm and blood stasis, providing a theoretical basis for TCM clinical treatment of this disease from phlegm and blood stasis.展开更多
维生素D为脂溶性类固醇衍生物,家族成员中最重要的成员是维生素D:和维生素D3。在人类,维生素D来源于阳光照射皮肤。皮肤合成的维生素D通过与维生素D结合蛋白(vitamin D binding protein,DBP)结合而运输到肝脏,而吸收的维生素D...维生素D为脂溶性类固醇衍生物,家族成员中最重要的成员是维生素D:和维生素D3。在人类,维生素D来源于阳光照射皮肤。皮肤合成的维生素D通过与维生素D结合蛋白(vitamin D binding protein,DBP)结合而运输到肝脏,而吸收的维生素D通过与乳糜微粒和脂蛋白结合转运到肝脏。在肝脏通过羟基化形成25羟基化维生素D[25-hydroxyvitamin D,25(OH)D],进而主要在肾脏和其他组织形成生物活性代谢物1,25双羟基化维生素D[1α,25-dihydroxyvitaminD,1α,25(OH)2D)]。维生素D缺乏在世界范围内普遍存在,影响着30%~50%的人。展开更多
文摘慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease, COPD)作为临床呼吸系统常见疾病之一,具有高患病率和高死亡率的特点,严重影响着慢性阻塞性肺疾病患者的生活质量,并给社会、家庭带来较大的经济和心理负担。常规西医治疗本病主要以积极对症治疗为主,而中医药对治疗慢性阻塞性肺疾病往往具有较好的临床疗效。本文通过分析近年来大量相关文献和临床研究,并结合中医药在临床辨治慢性阻塞性肺疾病的实际疗效,得出“从痰瘀论治慢性阻塞性肺疾病的临床效果较佳”,故以“痰瘀互结”理论为角度,从痰瘀型慢性阻塞性肺疾病的理论依据、临床治疗出发作出综述,为中医药临床从痰瘀治疗该病提供理论依据。Chronic Obstructive Pulmonary Disease (COPD), as one of the common diseases of clinical respiratory system, has the characteristics of the high morbidity and high mortality rate, which seriously affects the quality of life of patients with chronic obstructive pulmonary disease and brings a larger economic and psychological burden on society and family. Conventional Western medicine mainly focuses on the positive symptomatic treatment of this disease, while traditional Chinese medicine often has better clinical efficacy in the treatment of chronic obstructive pulmonary disease. Through analyzing a large number of relevant literature and clinical studies in recent years and combining with the actual therapeutic effect of traditional Chinese medicine in the clinical differentiation of chronic obstructive pulmonary disease, this paper concludes that “the clinical effect of treating chronic obstructive pulmonary disease from phlegm and blood stasis is better”. Therefore, based on the theory of “interjunction of phlegm and blood stasis”, this paper summarizes the theoretical basis and clinical treatment of chronic obstructive pulmonary disease with phlegm and blood stasis, providing a theoretical basis for TCM clinical treatment of this disease from phlegm and blood stasis.
文摘维生素D为脂溶性类固醇衍生物,家族成员中最重要的成员是维生素D:和维生素D3。在人类,维生素D来源于阳光照射皮肤。皮肤合成的维生素D通过与维生素D结合蛋白(vitamin D binding protein,DBP)结合而运输到肝脏,而吸收的维生素D通过与乳糜微粒和脂蛋白结合转运到肝脏。在肝脏通过羟基化形成25羟基化维生素D[25-hydroxyvitamin D,25(OH)D],进而主要在肾脏和其他组织形成生物活性代谢物1,25双羟基化维生素D[1α,25-dihydroxyvitaminD,1α,25(OH)2D)]。维生素D缺乏在世界范围内普遍存在,影响着30%~50%的人。